Leap Therapeutics, Inc. (LPTX)
Chart Events
Performance Outlook
| Previous Close | 1.8300 |
| Open | 1.8200 |
| Bid | 1.7900 x 1100 |
| Ask | 1.9000 x 1000 |
| Day's Range | 1.7800 - 1.8500 |
| 52 Week Range | 1.4300 - 3.2400 |
| Volume | 240,616 |
| Avg. Volume | 932,510 |
| Market Cap | 107.384M |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6340 |
| Earnings Date | Mar 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.30 |
- PR Newswire
Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the completion of enrollment for the first-line patient cohort in the DisTinGuish study, a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, with or without chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ).
- PR Newswire
Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of clinical data from its Phase 2 clinical trial of DKN-01 as a monotherapy and in combination with paclitaxel in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer, being held as a virtual meeting from March 19-25, 2021. DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, leading to the activation of the innate immune system in the tumor microenvironment and anti-tumor activity.
- Simply Wall St.
Introducing Leap Therapeutics (NASDAQ:LPTX), A Stock That Climbed 80% In The Last Year
Leap Therapeutics, Inc. ( NASDAQ:LPTX ) shareholders have seen the share price descend 16% over the month. But over the...
